Compare LGIH & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | DBVT |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 948.8M |
| IPO Year | 2013 | 2014 |
| Metric | LGIH | DBVT |
|---|---|---|
| Price | $64.06 | $16.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $75.90 | $32.04 |
| AVG Volume (30 Days) | ★ 379.1K | 311.8K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,705,504,000.00 | $5,636,000.00 |
| Revenue This Year | $2.32 | $35.04 |
| Revenue Next Year | $17.94 | $2,360.78 |
| P/E Ratio | $682.67 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $33.55 | $8.51 |
| 52 Week High | $69.42 | $26.19 |
| Indicator | LGIH | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 73.43 | 40.76 |
| Support Level | $41.87 | $16.05 |
| Resistance Level | N/A | $17.42 |
| Average True Range (ATR) | 3.06 | 0.98 |
| MACD | 0.86 | -0.01 |
| Stochastic Oscillator | 96.92 | 23.49 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.